Overview

Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride

Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if emixustat hydrochloride (ACU-4429) reduces the rate of progression of geographic atrophy compared to placebo in subjects with dry age-related macular degeneration.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Acucela Inc.
Kubota Vision Inc.
Collaborator:
Otsuka Pharmaceutical Co., Ltd.